Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.

Alonso-Álvarez S, Magnano L, Alcoceba M, Andrade-Campos M, Espinosa-Lara N, Rodríguez G, Mercadal S, Carro I, Sancho JM, Moreno M, Salar A, García-Pallarols F, Arranz R, Cannata J, Terol MJ, Teruel AI, Rodríguez A, Jiménez-Ubieto A, González de Villambrosia S, Bello JL, López L, Monsalvo S, Novelli S, de Cabo E, Infante MS, Pardal E, García-Álvarez M, Delgado J, González M, Martín A, López-Guillermo A, Caballero MD.

Br J Haematol. 2017 Sep;178(5):699-708. doi: 10.1111/bjh.14831. Epub 2017 Aug 7.

PMID:
28782811
2.

Plitidepsin: design, development, and potential place in therapy.

Alonso-Álvarez S, Pardal E, Sánchez-Nieto D, Navarro M, Caballero MD, Mateos MV, Martín A.

Drug Des Devel Ther. 2017 Jan 19;11:253-264. doi: 10.2147/DDDT.S94165. eCollection 2017. Review.

3.

Lymphoma Heterogeneity: Three Different Histological Pictures and One Unique Clone.

Alonso-Alvarez S, Redondo-Guijo A, Blanco Ó, Alcoceba M, Balanzategui A, Caballero JC, Dávila J, González M, Caballero MD, Martín A, García-Sanz R.

Case Rep Hematol. 2016;2016:3947510. Epub 2016 Oct 27.

4.

The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy.

Alonso-Álvarez S, Vidriales MB, Caballero MD, Blanco O, Puig N, Martin A, Peñarrubia MJ, Zato E, Galende J, Bárez A, Alcoceba M, Orfão A, González M, García-Sanz R.

Leuk Lymphoma. 2017 May;58(5):1144-1152. doi: 10.1080/10428194.2016.1239263. Epub 2016 Oct 12.

PMID:
27733075
5.

Characterizing College Science Assessments: The Three-Dimensional Learning Assessment Protocol.

Laverty JT, Underwood SM, Matz RL, Posey LA, Carmel JH, Caballero MD, Fata-Hartley CL, Ebert-May D, Jardeleza SE, Cooper MM.

PLoS One. 2016 Sep 8;11(9):e0162333. doi: 10.1371/journal.pone.0162333. eCollection 2016.

6.

Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS.

De La Serna J, Sanz J, Bermúdez A, Cabrero M, Serrano D, Vallejo C, Gómez V, Moraleda JM, Perez SG, Caballero MD, Conde E, Lahuerta JJ, Sanz G.

Bone Marrow Transplant. 2016 Jul;51(7):961-6. doi: 10.1038/bmt.2016.42. Epub 2016 Mar 7.

PMID:
26950372
7.

Management patterns and outcomes in symptomatic venous thromboembolism following allogeneic hematopoietic stem cell transplantation. A 15-years experience at a single center.

Labrador J, González-Rivero J, Monroy R, Lozano FS, López-Corral L, Caballero MD, Bastida JM, González-Porras JR.

Thromb Res. 2016 Jun;142:52-6. doi: 10.1016/j.thromres.2016.02.016. Epub 2016 Feb 18.

PMID:
26922092
8.

Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy.

Martín-Martín L, Almeida J, Pomares H, González-Barca E, Bravo P, Giménez T, Heras C, Queizán JA, Pérez-Ceballos E, Martínez V, Alonso N, Calvo C, Álvarez R, Caballero MD, Orfao A.

Oncotarget. 2016 Mar 1;7(9):10174-81. doi: 10.18632/oncotarget.7101.

9.

High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma.

Sebastián E, Alcoceba M, Martín-García D, Blanco Ó, Sanchez-Barba M, Balanzategui A, Marín L, Montes-Moreno S, González-Barca E, Pardal E, Jiménez C, García-Álvarez M, Clot G, Carracedo Á, Gutiérrez NC, Sarasquete ME, Chillón C, Corral R, Prieto-Conde MI, Caballero MD, Salaverria I, García-Sanz R, González M.

Ann Hematol. 2016 Jan;95(2):253-62. doi: 10.1007/s00277-015-2552-3. Epub 2015 Nov 14.

PMID:
26573278
10.

Challenge faculty to transform STEM learning.

Cooper MM, Caballero MD, Ebert-May D, Fata-Hartley CL, Jardeleza SE, Krajcik JS, Laverty JT, Matz RL, Posey LA, Underwood SM.

Science. 2015 Oct 16;350(6258):281-2. doi: 10.1126/science.aab0933. No abstract available.

PMID:
26472897
11.

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.

Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, Baetz T, Zelenetz AD, Gaidano G, Fayad LE, Buckstein R, Friedberg JW, Crump M, Jaksic B, Zinzani PL, Padmanabhan Iyer S, Sahin D, Chai A, Fingerle-Rowson G, Press OW.

J Clin Oncol. 2015 Oct 20;33(30):3467-74. doi: 10.1200/JCO.2014.59.2139. Epub 2015 Aug 17.

12.

Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile.

Martín-Martín L, López A, Vidriales B, Caballero MD, Rodrigues AS, Ferreira SI, Lima M, Almeida S, Valverde B, Martínez P, Ferrer A, Candeias J, Ruíz-Cabello F, Buadesa JM, Sempere A, Villamor N, Orfao A, Almeida J.

Oncotarget. 2015 Aug 7;6(22):19204-16.

13.

Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.

Panizo C, Rodríguez AJ, Gutiérrez G, Díaz FJ, González-Barca E, de Oña R, Grande C, Sancho JM, García-Álvarez MF, Sánchez-González B, Peñalver FJ, Cannata J, Espeso M, Requena MJ, Gardella S, Durán S, González AP, Alfonso A, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea GELTAMO Spanish Cooperative Group.

Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):398-403. doi: 10.1016/j.clml.2015.02.029. Epub 2015 Mar 5.

PMID:
25843416
14.

Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma.

Visani G, Stefani PM, Capria S, Malerba L, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Gonella R, Gobbi M, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Loscocco F, Isidori A.

Blood. 2014 Nov 6;124(19):3029-31. doi: 10.1182/blood-2014-08-596668. No abstract available.

15.

Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.

Pardal E, Coronado M, Martín A, Grande C, Marín-Niebla A, Panizo C, Bello JL, Conde E, Hernández MT, Arranz R, Bargay J, González-Barca E, Pérez-Ceballos E, Montes-Moreno S, Caballero MD.

Br J Haematol. 2014 Nov;167(3):327-36. doi: 10.1111/bjh.13036. Epub 2014 Jul 28.

PMID:
25066542
16.

ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.

Labrador J, Cabrero-Calvo M, Pérez-López E, Mateos MV, Vázquez L, Caballero MD, García-Sanz R.

Ann Hematol. 2014 Oct;93(10):1745-53. doi: 10.1007/s00277-014-2114-0. Epub 2014 May 27.

PMID:
24863692
17.

Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma.

Wilson WH, Bromberg JE, Stetler-Stevenson M, Steinberg SM, Martin-Martin L, Muñiz C, Sancho JM, Caballero MD, Davidis MA, Brooimans RA, Sanchez-Gonzalez B, Salar A, González-Barca E, Ribera JM, Shovlin M, Filie A, Dunleavy K, Mehrling T, Spina M, Orfao A.

Haematologica. 2014 Jul;99(7):1228-35. doi: 10.3324/haematol.2013.101741. Epub 2014 Apr 11.

18.

Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome.

Muñiz C, Martín-Martín L, López A, Sánchez-González B, Salar A, Almeida J, Sancho JM, Ribera JM, Heras C, Peñalver FJ, Gómez M, González-Barca E, Alonso N, Navarro B, Olave T, Sala F, Conde E, Márquez JA, Cabezudo E, Cladera A, García-Malo M, Caballero MD, Orfao A; Spanish Group for the Study of Central Nervous System Disease in Non-Hodgkin Lymphoma.

Blood. 2014 Mar 20;123(12):1864-9. doi: 10.1182/blood-2013-11-537993. Epub 2014 Feb 5.

19.

HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma.

Alcoceba M, Sebastián E, Marín L, Balanzategui A, Sarasquete ME, Chillón MC, Jiménez C, Puig N, Corral R, Pardal E, Grande C, Bello JL, Albo C, de la Cruz F, Panizo C, Martín A, González-Barca E, Caballero MD, San Miguel JF, García-Sanz R, González M.

Blood. 2013 Aug 22;122(8):1448-54. doi: 10.1182/blood-2013-02-483420. Epub 2013 Jul 10.

20.

How can we improve problem solving in undergraduate biology? Applying lessons from 30 years of physics education research.

Hoskinson AM, Caballero MD, Knight JK.

CBE Life Sci Educ. 2013 Jun 1;12(2):153-61. doi: 10.1187/cbe.12-09-0149.

21.

Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype.

Sebastián E, Alcoceba M, Balanzategui A, Marín L, Montes-Moreno S, Flores T, González D, Sarasquete ME, Chillón MC, Puig N, Corral R, Pardal E, Martín A, González-Barca E, Caballero MD, San Miguel JF, García-Sanz R, González M.

Am J Pathol. 2012 Nov;181(5):1879-88. doi: 10.1016/j.ajpath.2012.07.028. Epub 2012 Sep 11.

PMID:
22982190
22.

Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients.

Labrador J, Lopez-Anglada L, Perez-Lopez E, Lozano FS, Lopez-Corral L, Sanchez-Guijo FM, Vazquez L, Perez Rivera JA, Martin-Herrero F, Sanchez-Barba M, Guerrero C, del Cañizo MC, Caballero MD, San Miguel JF, Alberca I, Gonzalez-Porras JR.

Haematologica. 2013 Mar;98(3):437-43. doi: 10.3324/haematol.2012.069559. Epub 2012 Aug 16.

23.

BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.

Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Giardini C, Falcioni S, Cuberli F, Gobbi M, Sarina B, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Isidori A.

Blood. 2011 Sep 22;118(12):3419-25. doi: 10.1182/blood-2011-04-351924. Epub 2011 Aug 3.

24.

Flow cytometry immunophenotyping of fine-needle aspiration specimens: utility in the diagnosis and classification of non-Hodgkin lymphomas.

Barrena S, Almeida J, Del Carmen García-Macias M, López A, Rasillo A, Sayagués JM, Rivas RA, Gutiérrez ML, Ciudad J, Flores T, Balanzategui A, Caballero MD, Orfao A.

Histopathology. 2011 May;58(6):906-18. doi: 10.1111/j.1365-2559.2011.03804.x. Epub 2011 Mar 25.

PMID:
21438908
25.

Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03).

Tomás JF, Montalbán C, De Sevilla AF, Martínez-López J, Díaz N, Canales M, Martínez R, Sánchez-Godoy P, Caballero MD, Peñalver J, Prieto E, Salar A, Burgaleta C, Queizán JA, Bajo R, De Oña R, De La Serna J.

Leuk Lymphoma. 2011 Mar;52(3):409-16. doi: 10.3109/10428194.2010.543717. Epub 2011 Jan 28.

PMID:
21275633
26.

Ischemic stroke associated with the infusion of DMSO-cryopreserved auto-PBSCs.

González-López TJ, Sánchez-Guijo FM, Ortín A, Crusoe E, Cordoba I, Corral M, Vazquez L, Caballero MD.

Bone Marrow Transplant. 2011 Jul;46(7):1035-6. doi: 10.1038/bmt.2010.242. Epub 2010 Oct 18. No abstract available.

PMID:
20956954
27.

Cryptosporidium parvum infection vs GVHD after hematopoietic SCT: diagnosis by PCR with resolution of symptoms.

Sebastián E, Martín J, McDonald GB, Flores T, Rodríguez A, Blanco A, Vazquez L, de Fuentes I, Caballero MD.

Bone Marrow Transplant. 2011 Apr;46(4):612-4. doi: 10.1038/bmt.2010.156. Epub 2010 Jun 28. No abstract available.

PMID:
20581884
28.

Sustained complete remission with single agent rituximab in relapsed follicular lymphoma as transformed disease after unrelated reduced intensity conditioning allogeneic stem cell transplantation.

Puig N, Caballero MD, Alcoceba M, Sebastián E, Balanzategui A, Sarasquete ME, García-Sanz R, González-Díaz M.

Ann Hematol. 2011 Feb;90(2):227-9. doi: 10.1007/s00277-010-0987-0. Epub 2010 May 27. No abstract available.

29.

Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation.

Calvo-Villas JM, Martín A, Conde E, Pascual A, Heras I, Varela R, de la Rubia J, Ramirez MJ, Díez-Martín JL, Panizo C, Rodríguez-Salazar MJ, Pascual MJ, Donato EM, González-Barca E, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO cooperative group).

Ann Oncol. 2010 Sep;21(9):1891-7. doi: 10.1093/annonc/mdq035. Epub 2010 Mar 15.

PMID:
20231299
30.

Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients.

Chillón MC, Santamaría C, García-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M, Marín L, Caballero MD, Vidriales MB, Ramos F, Bernal T, Díaz-Mediavilla J, García de Coca A, Peñarrubia MJ, Queizán JA, Giraldo P, San Miguel JF, González M.

Haematologica. 2010 May;95(5):745-51. doi: 10.3324/haematol.2009.015073. Epub 2010 Feb 4.

31.

BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML).

Santamaría C, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Mateos MV, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizán JA, Rodríguez JN, Puig N, Balanzategui A, Sarasquete ME, Alcoceba M, Díaz-Mediavilla J, San Miguel J, González M.

Ann Hematol. 2010 May;89(5):453-8. doi: 10.1007/s00277-009-0864-x. Epub 2009 Nov 27.

PMID:
19943049
32.

High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics.

Santamaría CM, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizán JA, Rodriguez JN, Fernández-Abellán P, Bárez A, Peñarrubia MJ, Vidriales MB, Balanzategui A, Sarasquete ME, Alcoceba M, Díaz-Mediavilla J, San Miguel JF, Gonzalez M.

Leuk Res. 2009 Dec;33(12):1706-9. doi: 10.1016/j.leukres.2009.04.024. Epub 2009 May 19.

PMID:
19457552
33.

Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia.

Santamaría CM, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizán JA, Rodriguez JN, Fernández-Abellán P, Bárez A, Peñarrubia MJ, Balanzategui A, Vidriales MB, Sarasquete ME, Alcoceba M, Díaz-Mediavilla J, San Miguel JF, Gonzalez M.

Blood. 2009 Jul 2;114(1):148-52. doi: 10.1182/blood-2008-11-187724. Epub 2009 Apr 27.

34.

R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: influence of prior autologous stem-cell transplantation on outcome.

Martín A, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea.

Haematologica. 2009 May;94(5):744. doi: 10.3324/haematol.2009.006452. Epub 2009 Mar 31. No abstract available.

35.

R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.

Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, González-Barca E, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group).

Haematologica. 2008 Dec;93(12):1829-36. doi: 10.3324/haematol.13440. Epub 2008 Oct 22.

36.

Hematopoietic SCT for peripheral T-cell lymphoma.

Gutiérrez A, Caballero MD, Pérez-Manga G, Rodriguez J.

Bone Marrow Transplant. 2008 Dec;42(12):773-81. doi: 10.1038/bmt.2008.332. Epub 2008 Oct 20.

PMID:
18936735
37.

Clinical and prognostic value of discrepancies in microsatellite DNA regions between recipient and donor in human leukocyte antigen-identical allogeneic transplantation setting.

Alcoceba M, Balanzategui A, Díez-Campelo M, Martín-Jiménez P, Sarasquete ME, Chillón MC, Santamaría C, Pérez-Simón JA, Marín L, Caballero MD, San Miguel JF, García-Sanz R, González M.

Transplantation. 2008 Oct 15;86(7):983-90. doi: 10.1097/TP.0b013e318183ee2a.

PMID:
18852666
38.

Primary mediastinal large cell lymphoma (PMBL): frontline treatment with autologous stem cell transplantation (ASCT). The GEL-TAMO experience.

Rodríguez J, Conde E, Gutiérrez A, García JC, Lahuerta JJ, Varela MR, Pérez C, Albo C, Caballero MD.

Hematol Oncol. 2008 Sep;26(3):171-8. doi: 10.1002/hon.858.

PMID:
18432630
39.

Study protocol for a pragmatic randomised controlled trial in general practice investigating the effectiveness of acupuncture against migraine.

Vas J, Rebollo A, Perea-Milla E, Méndez C, Font CR, Gómez-Río M, Martín-Avila M, Carbrera-Iboleón J, Caballero MD, Olmos MA, Aguilar I, Faus V, Martos F.

BMC Complement Altern Med. 2008 Apr 14;8:12. doi: 10.1186/1472-6882-8-12.

40.

Molecular characterization of complete and incomplete immunoglobulin heavy chain gene rearrangements in hairy cell leukemia.

Martín-Jiménez P, García-Sanz R, González D, Balanzategui A, Pérez JJ, Caballero MD, Sarasquete ME, Galende J, Orfao A, López-Berges MC, San Miguel JF, González M.

Clin Lymphoma Myeloma. 2007 Nov;7(9):573-9.

PMID:
18186965
41.

Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma.

Rodríguez J, Gutierrez A, Palacios A, Navarrete M, Blancas I, Alarcón J, Caballero MD, De Mattos SF, Gines J, Martínez J, Lopez A.

Leuk Lymphoma. 2007 Nov;48(11):2172-8.

PMID:
17990179
42.

The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma.

Rodríguez J, Conde E, Gutiérrez A, Lahuerta JJ, Arranz R, Sureda A, Zuazu J, Fernández de Sevilla A, Bendandi M, Solano C, León A, Varela MR, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea, Spanish Lymphoma/Autologous Bone Marrow Transplant Study Group.

Haematologica. 2007 Aug;92(8):1067-74. Epub 2007 Jul 20.

43.

Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group.

Rodríguez J, Conde E, Gutiérrez A, Arranz R, León A, Marín J, Bendandi M, Albo C, Caballero MD; 'Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea' (GEL-TAMO).

Eur J Haematol. 2007 Jul;79(1):32-8.

PMID:
17598836
44.

Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.

Rodríguez J, Conde E, Gutiérrez A, Arranz R, Gandarillas M, Leon A, Ojanguren J, Sureda A, Carrera D, Bendandi M, Moraleda J, Ribera JM, Albo C, Morales A, García JC, Fernández P, Cañigral G, Bergua J, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea.

Eur J Haematol. 2007 Apr;78(4):290-6.

PMID:
17378891
45.

The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience.

Rodríguez J, Conde E, Gutiérrez A, Arranz R, León A, Marín J, Bendandi M, Albo C, Caballero MD.

Ann Oncol. 2007 Apr;18(4):652-7. Epub 2007 Jan 17.

PMID:
17229774
46.

Complete remission of subcutaneous panniculitic T-cell lymphoma after allogeneic transplantation.

Pérez-Persona E, Mateos-Mazón JJ, López-Villar O, Arcos MJ, Encinas C, Graciani IF, Ocio EM, Sánchez-Guijo FM, Caballero MD.

Bone Marrow Transplant. 2006 Dec;38(12):821-2. Epub 2006 Oct 23. No abstract available.

PMID:
17057727
47.

Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.

Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M, García-Conde J, Sanz G, Arranz R, Bernal MT, de la Serna J, Díez JL, Moraleda JM, Rubió-Félix D, Xicoy B, Martínez C, Mateos MV, Sierra J.

Biol Blood Marrow Transplant. 2006 Feb;12(2):172-83.

48.

Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.

Pérez-Simón JA, Díez-Campelo M, Martino R, Brunet S, Urbano A, Caballero MD, de León A, Valcárcel D, Carreras E, del Cañizo MC, López-Fidalgo J, Sierra J, San Miguel JF.

Br J Haematol. 2005 Aug;130(3):394-403.

PMID:
16042689
49.

Posttransplant hematopoiesis in patients undergoing sibling allogeneic stem cell transplantation reflects that of their respective donors although with a lower functional capability.

Sanchez-Guijo FM, Sanchez-Abarca LI, Villaron E, Lopez-Holgado N, Alberca M, Vazquez L, Perez-Simon JA, Lopez-Fidalgo J, Orfao A, Caballero MD, Del Cañizo MC, San Miguel JF.

Exp Hematol. 2005 Aug;33(8):935-43.

PMID:
16038787
50.

Long-term immune recovery of patients undergoing allogeneic stem cell transplantation: a comparison with their respective sibling donors.

Sanchez-Guijo FM, Sanchez-Abarca LI, Bueno C, Villaron E, Lopez-Holgado N, Vazquez L, Lopez-Fidalgo J, Perez-Simon JA, Caballero MD, del Cañizo MC, Orfao A, San Miguel JF.

Biol Blood Marrow Transplant. 2005 May;11(5):354-61.

Supplemental Content

Loading ...
Support Center